SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct

SELLAS Life Sciences Group, Inc.

2025-Q3 EPS reported -$0.20 vs consensus -$0.07 ▼ miss (-199.9%)

Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).
Cash and equivalents $44.3M at Sep 30, 2025; additional $29.1M net from warrant exercises in October.
Phase 3 REGAL trial of GPS in AML CR2 final analysis expected by year-end 2025 (80 events).
Phase 2 SLS009 in R/R AML data accepted for ASH 2025; trial in first-line AML to start Q1 2026.
R&D expense $4.2M (down 5% YoY); G&A expense $2.9M (down 3% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.